Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study
Caryn S Ross-Innes, Irene Debiram-Beecham, Maria O'Donovan, Elaine Walker, Sibu Varghese, Pierre Lao-Sirieix, Laurence Lovat, Michael Griffin, Krish Ragunath, Rehan Haidry, Sarmed S Sami, Philip Kaye, Marco Novelli, Babett Disep, Richard Ostler, Benoit Aigret, Bernard V North, Pradeep Bhandari, Adam Haycock, Danielle Morris, Stephen Attwood, Anjan Dhar, Colin Rees, Matthew D D Rutter, Peter D Sasieni, Rebecca C Fitzgerald, BEST2 Study Group, Karen Coker, Wanfeng Zhao, Kathryn Brown, Beverley Haynes, Tara Nuckcheddy Grant, Massimiliano di Pietro, Eleanor Dewhurst, Bincy Alias, Leanne Mills, Caroline Wilson, Elizabeth Bird-Lieberman, Jan Bornschein, Yean Lim, Kareem Shariff, Roberto Cayado Lopez, Myrna Udarbe, Claire Shaw, Glynis Rose, Ian Sargeant, M Al-Izzi, Roisin Schimmel, Elizabeth Green, Morgan Moorghen, Reshma Kanani, Mariann Baulf, Jayne Butcher, Adil Butt, Steve Bown, Vinay Sehgal, John Louis-Auguste, Darina Kohoutova, Sarah Kerr, Victor Eneh, Nigel Butter, Haroon Miah, David Graham, Rommel Butawan, Manuel Rodriguez-Justo, Alison Winstanley, Grace Adesina, Sabrina Holohan, Joan Idris, Nick Hayes, Shajahan Wahed, Nelson Kath Houghton, Marc Hopton, Anne Eastick, Debasis Majumdar, Kassem Manuf, Lyndsey Fieldson, Helen Bailey, Jacobo Fernandez-Sordo Ortiz, Mina Patel, Suzanne Henry, Samantha Warburton, Jonathan White, Lisa Gadeke, Beverley Longhurst, Richmond Abeseabe, Peter Basford, Rupam Bhattacharyya, Scott Elliot, Roisin Bevan, Carly Brown, Philippa Laverick, Gayle Clifford, Anita Gibbons, Julie Ingmire, Abdullah Mawas, Jacquelyn Harvey, Sharon Cave, Caryn S Ross-Innes, Irene Debiram-Beecham, Maria O'Donovan, Elaine Walker, Sibu Varghese, Pierre Lao-Sirieix, Laurence Lovat, Michael Griffin, Krish Ragunath, Rehan Haidry, Sarmed S Sami, Philip Kaye, Marco Novelli, Babett Disep, Richard Ostler, Benoit Aigret, Bernard V North, Pradeep Bhandari, Adam Haycock, Danielle Morris, Stephen Attwood, Anjan Dhar, Colin Rees, Matthew D D Rutter, Peter D Sasieni, Rebecca C Fitzgerald, BEST2 Study Group, Karen Coker, Wanfeng Zhao, Kathryn Brown, Beverley Haynes, Tara Nuckcheddy Grant, Massimiliano di Pietro, Eleanor Dewhurst, Bincy Alias, Leanne Mills, Caroline Wilson, Elizabeth Bird-Lieberman, Jan Bornschein, Yean Lim, Kareem Shariff, Roberto Cayado Lopez, Myrna Udarbe, Claire Shaw, Glynis Rose, Ian Sargeant, M Al-Izzi, Roisin Schimmel, Elizabeth Green, Morgan Moorghen, Reshma Kanani, Mariann Baulf, Jayne Butcher, Adil Butt, Steve Bown, Vinay Sehgal, John Louis-Auguste, Darina Kohoutova, Sarah Kerr, Victor Eneh, Nigel Butter, Haroon Miah, David Graham, Rommel Butawan, Manuel Rodriguez-Justo, Alison Winstanley, Grace Adesina, Sabrina Holohan, Joan Idris, Nick Hayes, Shajahan Wahed, Nelson Kath Houghton, Marc Hopton, Anne Eastick, Debasis Majumdar, Kassem Manuf, Lyndsey Fieldson, Helen Bailey, Jacobo Fernandez-Sordo Ortiz, Mina Patel, Suzanne Henry, Samantha Warburton, Jonathan White, Lisa Gadeke, Beverley Longhurst, Richmond Abeseabe, Peter Basford, Rupam Bhattacharyya, Scott Elliot, Roisin Bevan, Carly Brown, Philippa Laverick, Gayle Clifford, Anita Gibbons, Julie Ingmire, Abdullah Mawas, Jacquelyn Harvey, Sharon Cave
Abstract
Background: Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophageal adenocarcinoma. Routine endoscopic screening for BE is not recommended because of the burden this would impose on the health care system. The objective of this study was to determine whether a novel approach using a minimally invasive cell sampling device, the Cytosponge, coupled with immunohistochemical staining for the biomarker Trefoil Factor 3 (TFF3), could be used to identify patients who warrant endoscopy to diagnose BE.
Methods and findings: A case-control study was performed across 11 UK hospitals between July 2011 and December 2013. In total, 1,110 individuals comprising 463 controls with dyspepsia and reflux symptoms and 647 BE cases swallowed a Cytosponge prior to endoscopy. The primary outcome measures were to evaluate the safety, acceptability, and accuracy of the Cytosponge-TFF3 test compared with endoscopy and biopsy. In all, 1,042 (93.9%) patients successfully swallowed the Cytosponge, and no serious adverse events were attributed to the device. The Cytosponge was rated favorably, using a visual analogue scale, compared with endoscopy (p < 0.001), and patients who were not sedated for endoscopy were more likely to rate the Cytosponge higher than endoscopy (Mann-Whitney test, p < 0.001). The overall sensitivity of the test was 79.9% (95% CI 76.4%-83.0%), increasing to 87.2% (95% CI 83.0%-90.6%) for patients with ≥3 cm of circumferential BE, known to confer a higher cancer risk. The sensitivity increased to 89.7% (95% CI 82.3%-94.8%) in 107 patients who swallowed the device twice during the study course. There was no loss of sensitivity in patients with dysplasia. The specificity for diagnosing BE was 92.4% (95% CI 89.5%-94.7%). The case-control design of the study means that the results are not generalizable to a primary care population. Another limitation is that the acceptability data were limited to a single measure.
Conclusions: The Cytosponge-TFF3 test is safe and acceptable, and has accuracy comparable to other screening tests. This test may be a simple and inexpensive approach to identify patients with reflux symptoms who warrant endoscopy to diagnose BE.
Conflict of interest statement
The Addenbrooke's Hospital Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre, supported this study. This study was funded by a project grant from Cancer Research UK. The device was designed by RCF and her research team in between 2009 and 2010. Patents and a trademark were filed in 2010 by the Medical Research Council (MRC). The BEST2 study was designed in 2010 and the device was manufactured for the specific purpose of this study following a letter of no objection from the Medical Health Regulatory Agency. In 2013 the MRC licensed the technology to Covidien GI Solutions. They have had no influence in any way on the design, conduct or analysis of this trial and the manuscript was not disclosed to them until after acceptance for publication. RCF, MOD and PLS are named inventors on patents pertaining to the Cytosponge and related assays. They have not received any financial benefits to date. Since December 2013, after completion of this study, PLS is now employed partly by Covidien GI Solutions. All other authors have no conflicts of interest to declare. RCF has programmatic funding from the Medical Research Council and infrastructure support from the Biomedical Research Centre and the Experimental Medicine Centre. MDDR has received travel reimbursement for conferences (Abbvie 2014), honoraria (Dr Falk 2013), unrestricted grant research (Olympus 2014) and shares (AstraZeneca, held for >20 years).
Figures
References
- Dent J, El-Serag HB, Wallander MA, Johansson S (2005) Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54: 710–717.
- Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, et al. (2012) Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143: 1179–1187. 10.1053/j.gastro.2012.08.002
- Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, et al. (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129: 1825–1831.
- Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, et al. (2008) Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 57: 1354–1359. 10.1136/gut.2007.145177
- Gerson LB, Shetler K, Triadafilopoulos G (2002) Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 123: 461–467.
- Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RKH, et al. (2003) Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125: 1670–1677.
- Ward EM, Wolfsen HC, Achem SR, Loeb DS, Krishna M, et al. (2006) Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 101: 12–17.
- Lao-Sirieix P, Fitzgerald RC (2012) Screening for oesophageal cancer. Nat Rev Clin Oncol 9: 278–287. 10.1038/nrclinonc.2012.35
- Desai TK, Krishnan K, Samala N, Singh J, Cluley J, et al. (2012) The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 61: 970–976. 10.1136/gutjnl-2011-300730
- Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P (2011) Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 365: 1375–1383. 10.1056/NEJMoa1103042
- Zehetner J, DeMeester SR, Hagen JA, Ayazi S, Augustin F, et al. (2011) Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma. J Thorac Cardiovasc Surg 141: 39–47. 10.1016/j.jtcvs.2010.08.058
- Spechler SJ (2013) Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 310: 627–636. 10.1001/jama.2013.226450
- Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, et al. (2014) British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 63: 7–42. 10.1136/gutjnl-2013-305372
- Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, et al. (2004) A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 127: 310–330.
- Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, et al. (2013) Impact of endoscopic surveillance on mortality From Barrett's esophagus–associated esophageal adenocarcinomas. Gastroenterology 145: 312–319. 10.1053/j.gastro.2013.05.004
- Bhat SK, McManus DT, Coleman HG, Johnston BT, Cardwell CR, et al. (2014) Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study. Gut 64: 20–25. 10.1136/gutjnl-2013-305506
- Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, et al. (2014) Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 311: 1209–1217. 10.1001/jama.2014.2511
- Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, et al. (2009) Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 360: 2277–2288. 10.1056/NEJMoa0808145
- Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, et al. (2013) Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 145: 87–95. 10.1053/j.gastro.2013.03.045
- Kadri SR, Lao-Sirieix P, O'Donovan M, Debiram I, Das M, et al. (2010) Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 341: c4372 10.1136/bmj.c4372
- Lao-Sirieix P, Boussioutas A, Kadri SR, O'Donovan M, Debiram I, et al. (2009) Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 58: 1451–1459. 10.1136/gut.2009.180281
- Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, et al. (1993) An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 105: 40–50.
- Armitage P (1955) Tests for linear trends in proportions and frequencies. Biometrics 11: 375–386.
- Clopper C, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26: 404–413.
- Weaver JMJ, Ross-Innes C, Shannon N, Lynch AG, Forshew T, et al. (2014) Ordering of mutations in preinvasive disease stages of oesophageal carcinogenesis. Nat Genet 46: 837–843. 10.1038/ng.3013
- Wani S, Falk G, Hall M, Gaddam S, Wang A, et al. (2011) Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 9: 220–227. 10.1016/j.cgh.2010.11.008
- Weston AP, Sharma P, Mathur S, Banerjee S, Jafri AK, et al. (2004) Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol 99: 1657–1666.
- Pohl H, Arash H, Ell C, Manner H, May A, et al. (2014) Length of Barrett's esophagus and cancer risk—implications from a population based study [abstract]. Digestive Disease Week 2014; 3–6 May 2014; Chicago, Illinois, US. Gastroenterology 146: S-122 10.1053/j.gastro.2014.04.029
- Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW (2002) The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 50: 378–381.
- Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370: 1287–1297. 10.1056/NEJMoa1311194
- Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, et al. (2011) Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 155: 687–697. 10.7326/0003-4819-155-10-201111150-00376
- Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011) American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140: 1084–1091. 10.1053/j.gastro.2011.01.030
- Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011) American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 140: e18–52. 10.1053/j.gastro.2011.01.031
- Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G (2013) Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 144: 62–73.e66. 10.1053/j.gastro.2012.09.060
- Thrift AP, Kendall BJ, Pandeya N, Vaughan TL, Whiteman DC, et al. (2012) A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila) 5: 1115–1123.
- Liu X, Wong A, Kadri SR, Corovic A, O'Donovan M, et al. (2014) Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus. PLoS ONE 9: e94163 10.1371/journal.pone.0094163
- Steele RJC, McClements PL, Libby G, Black R, Morton C, et al. (2009) Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 58: 530–535. 10.1136/gut.2008.162883
- Kavanagh AM, Giles GG, Mitchell H, Cawson JN (2000) The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status. J Med Screen 7: 105–110.
Source: PubMed